| abstract |
The present disclosure relates to engineered antibodies which, when administered to humans, exhibit low levels of immunogenicity in humans. The present disclosure also relates to methods of generating antibodies. Engineered antibodies can be derived, for example, from non-human (eg murine) donor antibodies or from chimeric or humanized antibodies, which are known to induce neutralizing anti-antibody responses in humans when administered chronically to humans. Predicted, or predicted. |